奥曲肽长效释放剂联合托伐普坦治疗常染色体显性多囊肾病患者的试验:先导性、随机、安慰剂对照、交叉试验
本先导性随机安慰剂对照交叉试验在19例常染色体显性多囊肾病患者中比较托伐普坦联合奥曲肽长效释放剂与托伐普坦联合安慰剂对肾小球滤过率的影响,结果显示联合治疗在1周和4周时降低肾小球滤过率更明显,且显著减小总肾体积并减轻托伐普坦的水利尿效应。
要点
- 治疗4周,托伐普坦联合奥曲肽组肾小球滤过率中位下降7 ml/min/1.73 m²,联合安慰剂组下降3 ml/min/1.73 m²。
- 治疗1周,联合奥曲肽组肾小球滤过率中位下降10 ml/min/1.73 m²,联合安慰剂组下降3 ml/min/1.73 m²,组间差异有统计学意义。
- 联合奥曲肽组总肾体积中位下降41 ml,联合安慰剂组变化无统计学意义。
核心结论
- 在常染色体显性多囊肾病患者中,托伐普坦联合奥曲肽长效释放剂较托伐普坦联合安慰剂更有效地降低肾小球滤过率。
- 奥曲肽长效释放剂还减小总肾体积和囊性肾体积,并减轻托伐普坦的水利尿效应。
研究设计与样本
- 先导性、随机、安慰剂对照、交叉试验,纳入19例转诊至意大利临床研究中心的常染色体显性多囊肾病患者,分析采用意向性治疗。
- 奥曲肽长效释放剂为两次20 mg肌内注射,安慰剂为两次肌内注射0.9%氯化钠溶液,均联合托伐普坦(剂量分别至90 mg/d和30 mg/d)。
- 主要比较1周和4周治疗对肾小球滤过率(碘海醇血浆清除率)的影响。
- 当地伦理委员会批准了该研究。
主要发现
- 4周时,托伐普坦联合安慰剂组肾小球滤过率中位下降3(-1至5)ml/min/1.73 m²(P=0.01),托伐普坦联合奥曲肽长效释放剂组下降7(3至14)ml/min/1.73 m²(P=0.03),两个治疗期肾小球滤过率变化相差2(-5至14)ml/min/1.73 m²(P=0.28)。
- 1周时,托伐普坦联合安慰剂组肾小球滤过率中位下降3(0至7)ml/min/1.73 m²(P=0.006),托伐普坦联合奥曲肽长效释放剂组下降10(-6至16)ml/min/1.73 m²(P<0.001),两个治疗期肾小球滤过率变化相差3(0至12)ml/min/1.73 m²(P=0.012)。
- 托伐普坦联合安慰剂组总肾体积中位变化为4(-48至23)ml(P=0.74),无统计学意义;托伐普坦联合奥曲肽长效释放剂组总肾体积中位下降41(25至77)ml(P=0.001),两个治疗期总肾体积变化相差36(0至65)ml(P=0.01)。
- 奥曲肽长效释放剂减轻了托伐普坦的水利尿效应(P=0.02)。
- 治疗耐受性良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tolvaptan and octreotide-long-acting release (LAR) have renoprotective effects in autosomal dominant polycystic kidney disease (ADPKD) that are partially mediated by amelioration of compensatory glomerular hyperfiltration. We compared the effects of tolvaptan and octreotide-LAR combination therapy versus those of tolvaptan monotherapy in patients with ADPKD. METHODS: This pilot, randomized, placebo-controlled, cross-over trial primarily compared the effects of 1- and 4-week treatments with octreotide-LAR (two 20-mg i.m. injections) or placebo (two i.m. 0.9% saline solution injections) added-on tolvaptan (up to 90 and 30 mg/d) on GFR (iohexol plasma clearance) in 19 consenting patients with ADPKD referred to a clinical research center in Italy. Analyses were intention-to-treat. The local ethical committee approved the study. RESULTS: At 4 weeks, GFR significantly decreased by a median (interquartile range) of 3 (-1 to 5) ml/min per 1.73 m2 with tolvaptan and placebo (P=0.01) and by 7 (3-14) ml/min per 1.73 m2 with tolvaptan and octreotide-LAR (P=0.03). GFR changes during the two treatment periods differed by 2 (-5 to 14) ml/min per 1.73 m2 (P=0.28). At 1 week, GFR significantly decreased by 3 (0-7) ml/min per 1.73 m2 with tolvaptan and placebo (P=0.006) and by 10 (-6 to 16) ml/min per 1.73 m2 with tolvaptan and octreotide-LAR add-on therapy (P<0.001). GFR changes during the two treatment periods significantly differed by 3 (0-12) ml/min per 1.73 m2 (P=0.012). Total kidney volume nonsignificantly changed by 4 (-48 to 23) ml with tolvaptan and placebo (P=0.74), whereas it decreased significantly by 41 (25-77) ml with tolvaptan and octreotide-LAR (P=0.001). Changes during the two treatment periods differed by 36 (0-65) ml (P=0.01). Octreotide-LAR also attenuated (P=0.02) the aquaretic effect of tolvaptan. Treatments were well tolerated. CONCLUSIONS: In patients with ADPKD, octreotide-LAR added-on tolvaptan reduced GFR more effectively than octreotide-LAR and placebo. Octreotide-LAR also reduced total and cystic kidney volumes and attenuated the acquaretic effect of tolvaptan. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL), NCT03541447.
引用
- Trillini M, Caroli A, Perico N, et al. Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial. Clin J Am Soc Nephrol. 2023. PMID: 36754009. doi:10.2215/CJN.0000000000000049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。